07-10-2022, 05:23 PM
China-developed neutralizing antibody combination therapy enters market; effective against BA.4, BA.5: experts
![[Image: 4844c847-18c0-4a84-a071-0ad494f40dee.jpeg]](https://www.globaltimes.cn/Portals/0/attachment/2021/2021-12-09/4844c847-18c0-4a84-a071-0ad494f40dee.jpeg)
China-developed neutralizing antibody combination COVID-19 therapeutic drugs have been made available for commercial sale. The drugs are effective in combating the fast transmitting BA.4 and BA.5, industry experts said on Friday.
The therapy, designated BRII-196/BRII-198, was jointly developed by Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences, and is the first novel coronavirus neutralizing antibody combination therapeutic holding independent intellectual property rights approved in China.
The therapy is effective in combating the current BA.5 and also BA.2 strains detected in some cities in China based on our study, Zhu Qing, Senior Vice President, head of Biopharmaceutical Research, Brii Biosciences told the Global Times on Friday. Zhu said they are still conducting further study on inhibiting the reproduction of mutant strains.
- More -